Ampersand Capital Partners-backed N2 Biomedical to merge with Precision Coating.

Ampersand Capital Partners-backed N2 Biomedical, a provider of nano-engineered surface treatment and coating services, agreed to merge with Precision Coating, a medical coatings service provider. Financial terms were not disclosed. "We are very excited to add N2's technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers. This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants," Bill Ellerkamp, Precision Coating President.